Anavex Life Sciences Corp.

AVXL | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.40

-$0.02 (-0.83%)

At close: Sep 21, 2026, 4:00 PM ET

$2.43

+$0.03 (+1.25%)

Pre-market: Sep 22, 2026, 4:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.83%

(1D)

Rating

Updated: Aug 26, 2026

16.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $222.41M

1D Range

2.35 2.41

52W Range

2.26 10.38

Valuation (TTM)

PE -16

PB 1.98

EV/EBITDA -8.75

Valuation (NTM)

Forward PE 16.11

Forward PEG -0.14

Price Target $11

Cash Flow

FCF Yield -12.7%

SBC Adj. FCF Yield -16.8%

SBC Impact -32.4%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 43.0% | 19.8%

FCF 3Y | 5Y 7.1% | -1.5%

Returns

ROA -20.0%

ROE -21.1%

ROIC -27.3%

Financial Health

Net Cash

$118.33M

Current Ratio 15.62

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leadin...

Sector Healthcare

Industry Biotechnology

Employees 34

IPO Date Aug 1, 2006

Website www.anavex.com

Fiscal Year October - September

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$11

Upside

+358.33%

Buy (2)

Hold (1)

Sell (0)

Analyst Details ➞